semaj83/ctmatch_classification huggingface dataset:
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Lymphoma, B-Cell Histologically confirmed Diffuse Large B-Cell Lymphoma (DLBCL) not otherwise specified (NOS) Previously untreated disease Age 18-60 Age adjusted IPI=2-3 Ann Arbor stage II-IV disease Measurable disease ≥ 1.5 cm in longest diameter, and measurable in 2 perpendicular dimensions Normal blood count as defined as: absolute neutrophil count ≥1.0 × 109/L independent of growth factor support, platelet count ≥ 100,000/mm3 or ≥50,000/mm3 if bone marrow (BM) involvement independent of transfusion support in either situation Normal organ functions defined as: creatinine ≤2 times the upper limit of normal (ULN) or estimated Glomerular Filtration Rate (Cockroft Gault) ≥40 ml/min/1.73m2, aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤3× the ULN; total bilirubin ≤ 1.5 × the ULN unless bilirubin rise is due to Gilbert's syndrome or of nonhepatic origin: patients with documented Gilbert disease may be enrolled if total bilirubin is ≤ 3.0 × the ULN; International normalized ratio (INR) < 1.5 × the ULN in the absence of therapeutic anticoagulation; partial thromboplastin time (PTT) or activated partial thromboplastin time (aPTT) < 1.5 × the ULN in the absence of a lupus anticoagulant" Patients with occult or prior hepatitis B infection (defined as HBsAg negative, anti-HBs positive and /or anti-HBc positive) may be included if hepatitis B virus (HBV) DNA is undetectable. These patients must be willing to undergo bi-monthly DNA testing and they should receive prophylaxis with Lamivudine  Any Other histologies than Diffuse Large B Cell Lymphoma (DLBCL): composite or transformed disease and patients with follicular lymphoma IIIB Primary mediastinal lymphoma (PMBL) Known central nervous system lymphoma Any prior lymphoma therapy Contraindication to any drug in the chemotherapy regimen Left ventricular ejection fraction (LVEF) < 50% Neuropathy ≥ grade 2 Seropositive for or active viral infection with HBV HBsAg positive
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-85.0,  Subarachnoid Hemorrhage Patients diagnosed by CT scan or MRI with subarachnoid hemorrhage and admitted to the neurological ICU >48 hours  Significant language barrier that would limit the ability to participate in the physical therapy program Severe baseline physical or cognitive impairment that would impair their ability to participate in the protocol Patients whose vital signs are outside the accepted starting and stopping outlined below: 1. intracranial pressure ≤ 15 mm Hg 2. Cerebral perfusion pressure >50 or <70 mm Hg 3. Mean arterial pressure ≥ 80 and ≤ 110 4. Heart rate ≥40 and <140 bpm 5. Pulse oximetry >88%
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-85.0,  Vitamin D Deficiency Known vitamin D deficiency based on blood work obtained prior to study consent defined as serum 25-hydroxyvitamin D less than or equal to 20 ng/mL within 30 days prior to study entry. 2. Adult, age 18 to 85 years, male or female 3. If on oral vitamin D therapy, have been on a stable dose for the previous 90 days  History of chronic liver disease with elevated liver function tests, chronic kidney disease (stage 3 or greater, eGFR <60 mL/min), uncontrolled thyroid disease (elevated thyroid function tests), primary or secondary hyperparathyroidism, hypercalcemia, or multiple endocrine neoplasia. 2. Hypercalcemia defined as either elevated corrected serum calcium >10.2 mg/dL) measured within 3 months prior to study. 3. estimated glomerular filtration rate (eGFR) <60 mL/min within 3 months prior to study. 4. Active cancers 5. Women who are pregnant or breastfeeding. 6. Individuals who are unable to give informed consent 7. Individuals with psoriasis, active eczema or other skin disease, or who are currently receiving treatments or medications for skin disease. 8. Individuals who do not agree to refrain from using tanning beds for the duration of the study. 9. Individuals who do not agree to avoid submerging the ointment site in water for 8 hours after ointment application
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 19.0-999.0,  Sickle Cell Disease Recipient Age greater than or equal to 19 years Diagnosis of sickle cell disease (HB SS, SC, or SBeta-thal(0)); confirmed by hemoglobin electrophoresis, high-performance liquid chromatography, DNA testing when necessary or both At high risk for disease-related morbidity or mortality, defined by having at least one of the following manifestations (A-E) A: Clinically significant neurologic event (stroke) or any neurological deficit lasting > 24 hours B: History of two or more episodes of acute chest syndrome (ACS) in the 2-year period preceding enrollment despite the institution of supportive care measures including hydroxyurea C: Three or more pain crises per year in the 2-year period preceding referral (required intravenous pain management in the outpatient or inpatient hospital setting) despite the institution of supportive care measures including hydroxyurea D: Administration of regular RBC transfusion therapy, defined as receiving 8 or more transfusions per year for ≥ 1 year to prevent vaso-occlusive clinical complications (i.e. pain, stroke, acute chest syndrome, and priapism) E: Pulmonary hypertension (defined as tricuspid regurgitant jet velocity (TRV) ≥2.5 m/s at baseline (without vaso-occlusive crisis) Any one of the below complications not ameliorated by hydroxyurea at the maximum tolerated dose for at least 6 months  Detectable antibody to ABO, Rh, or other red blood cell antigen of their donors Presence of donor specific antibodies detected by donor specific antibody screen (if using product from a haploidentical donor) Karnofsky/Lansky performance score < 60 Evidence of uncontrolled bacterial, viral, or fungal infections (currently taking medication and progression of clinical symptoms) within one month prior to starting the conditioning regimen. Patients with fever or suspected minor infection should await resolution of symptoms before starting the conditioning regimen Poor cardiac function defined as left ventricular ejection fraction < 40% Poor pulmonary function defined as FEV1 and FVC < 40% predicted or diffusing capacity of the lung for carbon monoxide (DLCO) < 40% (corrected for hemoglobin) Poor liver function defined as direct bilirubin > 2x upper limit of normal for age and alanine aminotransferase (ALT) and aspartate aminotransferase (AST) > 5 times upper limit of normal Poor kidney function defined by creatinine clearance < 70mL/min HIV-positive Unwillingness to use approved contraception method from time of biologic assignment until discontinuation of all immunosuppressive medications
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Non Small Cell Lung Cancer For in the study subjects should fulfill the following 1. Provision of written informed consent to treatment and companion translational studies prior to any study specific procedures 2. Patients must be > 18 years of age. 3. Affiliation to an health insurance 4. Histological diagnosis of NSCLC 5. Advanced or metastatic disease (stage IIIB/IV) 6. Access to the original tumor biopsy or planning of a fresh tumor biopsy before start the platinium based chemotherapy 7. Chemonaive for NSCLC or patient having received adjuvant chemotherapy at least 2 years before trial enrolment or patient currently receiving his/her first platinum-based chemotherapy for advanced NSCLC (first line or second line only if the first line was an anti-PD-1 or anti-PD-L1 agent monotherapy) 8. No other cancer in the previous 3 years, except cervical cancer or cutaneous cancer 9. Absence of EGFR-sensitising mutation or ALK translocation 10. ECOG Performance Status of 0-1 11. Fit to receive 6 cycles or currently receiving of platinum-based induction chemotherapy 12. At the start of the platinium based induction chemotherapy measurable lesions by v1.1 i.e. at least one lesion, not previously irradiated, that can be accurately measured at baseline as ≥ 10mm in the longest diameter (except lymph nodes that must have short axis ≥ 15mm) with computed tomography (CT), magnetic resonance imaging (MRI) or clinical examination and which is suitable for accurate repeated measurements. 13 is only for patients registered before starting the platinum-based induction chemotherapy: 13. Patients must have normal organ and bone marrow function measured within 14 days prior to administration of the platinum based treatment Haemoglobin ≥ 10.0 g/dL Absolute neutrophil count (ANC) ≥ 1.5 x 109/L Platelet count ≥ 100 x 109/L Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) AST (SGOT)/ALT (SGPT) ≤ 2.5 x institutional upper limit of normal unless liver metastases are present in which case it must be ≤ 5x ULN Creatinine clearance > 60mL/min as calculated by Cockroft-Gault formula for cisplatin administration; creatinine clearance >/= 51mL/min by Cockroft-Gault formula for carboplatin administration 14. Evidence of non-childbearing status for women of childbearing potential: negative serum pregnancy test within 14 days of study treatment. Postmenopausal is defined as Amenorrheic for 1 year or more following cessation of exogenous hormonal treatments LH and FSH levels in the post-menopausal range for women under 50 Radiation-induced oophorectomy with last menses >1 year ago
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-100.0,  Atrial Fibrillation Admission with atrial fibrillation developing atrial fibrillation during hospitalization for mon AF reason age 18 or more years patients welling to participate in the registry  age less than 18 years patients not welling to participate
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-49.0,  Normal Physiology Healthy Healthy women and men will be eligible for study participation if they meet the following A participant will have passed his/her 18th birthday and will not have attained the age of 50 at the time of enrollment Willing to allow storage of their biological samples Able to comply with study procedures and swallow capsules  An individual who meets any of the following will be excluded from study participation Body Mass Index (BMI) greater than or equal to 35 or less than or equal to 18 kg/M(2) Vital signs outside of acceptable range at Screening Visit, i.e., blood pressure >160/100, oral temperature >100 degrees F, pulse >100 Use of any of the following drugs or devices within the last 6 months systemic antibiotics, antifungals, antivirals, or antiparasitics (intravenous, intramuscular, or oral) oral, intravenous, intramuscular, nasal, or inhaled corticosteroids cytokines methotrexate or immunosuppressive cytotoxic agents large doses of commercial probiotics consumed (greater than or equal to 10(8) cfu or organisms per day), including tablets, capsules, lozenges, chewing gum, or powders in which probiotic is a primary component. Ordinary dietary components such as fermented beverages/milks, yogurts, and foods do not apply anabolic steroids
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 30.0-59.0,  Impaired Glucose Tolerance BMI: 25.0-34.99 kg / m2 Diagnosis of IGT (2h-OGTT Values between 140mg / dl and 199mg / dl.) Written informed consent body weight stable over the last 3 months Women in follicular phase of the menstrual cycle (days 3 to 8 of the cycle) at the time of laboratory tests Women who are not contemplated get pregnant within the next 6 months  Women pregnant or breastfeeding Physical or mental disability that makes it impossible to perform the intervention Diagnosis of hypertension or heart failure Smokers Untreated thyroid disease Consumption of oral agents or other medications or supplements with proven properties that modify the behavior of glucose and lipids (oral hypoglycemic agents, insulin, lipid-lowering) Diagnosis of liver disease or elevation twice of the upper normal value of liver enzymes Diagnosis of renal disease or creatinine > 1.5 mg / dl Diagnosis of Type 2 Diabetes Mellitus (T2DM) Fasting glucose ≥ 126 mg / dL and/or 2h-OGTT ≥ 200 mg / dL and/or A1C ≥ 6.5% Total Cholesterol ≥ 280 mg/dL
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 19.0-35.0,  No Condition, Healthy Females Healthy females  musculoskeletal and neurological disorder history of high blood pressure heart disease rheumatologic disease that affected the mobility unstable cardio respiratorydisorder cardiovascular disorder
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 65.0-79.0,  Obesity Weight Loss Age 65-79 years BMI=30-40 kg/m2 Confirmation of self-reported mobility disability, as assessed by phone screen/clinical staff Self-reported sedentary behavior Non-impaired cognitive function (MoCA>18) Stability of residence for next 2 years Willing and able to follow dietary protocol Willing to provide informed consent Approved for participation by study physician Not involved in another behavioral or interventional research study  Weight loss or gain (±5%) in past 6 months Prior bariatric surgery Multiple food allergies Difficulty with hearing/vision that interferes with study participation Excessive alcohol use (>14 drinks/week) Smoker (>1 cigarette/d within year) Insulin-dependent or uncontrolled diabetes (FBG >140 mg/dl) Uncontrolled hypertension (BP>160/100 mmHg) Abnormal kidney tests (GFR<40, creatinine >2.0) Regular use of medications that may influence body weight or composition
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 6.0-14.0,  Asthma Patients aged between 6 and 14 years old, of both sexes Diagnosis of mild / moderate persistent asthma (GINA step 2/3) Allergy mite (Dermatophagoides farinae and pteronyssinus + + + / + + + +) Levels of vitamin 25 (OH) D <30 ng / ml Signature of the informed consent of one parent or a legal representative  Cardiovascular disease or systemic anatomical abnormalities Other respiratory diseases Taking probiotics and / or prebiotics in the previous 2 weeks Taking vitamin D or systemic corticosteroids within 4 weeks Participation in other clinical trials
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Thoracic Surgery Atrial Fibrillation in High Risk Patients Patients ≥18 years old scheduled for elective thoracic surgery (segmentectomy, lobectomy or bi-lobectomy, pneumonectomy or esophagectomy) and meeting one of the four following risk Female & BNP ≥ 25pg/ml (no age limit) Male gender <75 & BNP ≥ 25pg/ml Male age ≥75 (No BNP limit) History of prior AF Patients in sinus rhythm Patients with stable respiratory status (no respiratory distress) Patients capable of providing written, informed consent  Patients scheduled for extrapleural pneumonectomy Hemodynamically unstable patients (not in cardiogenic shock or having an acute MI) Patients with 2nd or 3rd degree atrioventricular (AV) block Patients with hypersensitivity to amiodarone or NAC Patients already taking class Ic or III antiarrhythmic drugs Hepatic insufficiency (≤2 times the upper normal limit of transaminase levels) Renal insufficiency (creatinine ≥2.0 mg/dl) Known pregnancy
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 30.0-80.0,  ALS For the patients  Man or woman with sporadic ALS and a possible, probable or definite diagnosis regarding the revised Escorial (Forbes et al., 2001). Patients are followed quarterly according to national recommendations. At the end of the follow up period (1 year for each patient), all patients remaining in the " possible " group of diagnosis will be excluded Disease onset (date of onset of muscle weakness) < 18 months at the time of inclusion Age: 30 to 80 years-old, inclusive Patient treated by riluzole at a steady dosage since at least 3 months Patient accepting to give informed consent  will be  A previous treatment with VD in the preceding 2 years, whatever the dose used Patient with an already known autoimmune disorder Patient with severe ALS involvement suggesting that survival over the 1 year follow up is highly unlikely (ex : tetraplegia, use of non-invasive ventilation for more than 10 hrs/day, (ALS Functional Rating Scale) score < à 20) Pregnant or breast-feeding woman Patient without social security insurance For the Controls: Controls will be spouses of our ALS patients. Such a group has the advantage of similar life style conditions, and frequently similar geographical origin. Controls and ALS patients will match for age and gender. Controls will also fulfill the following and •Subject accepting to give informed consent Subject with an already known neurodegenerative disorder Subject with an already known autoimmune disorder Subject who received a treatment with VD in the preceding 2 years, whatever the dose used
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Osteoarthritis Subjects must meet all of the following to be considered for in the study. 1. Subject is between 18 and 75 years of age 2. Subject is indicated for a unilateral or bilateral total hip arthroplasty (THA) based on the approved labeling of the device 3. Subject has no history of previous prosthetic replacement device or orthopedic surgeries on the operative hip 4. Subject is willing and able to provide informed consent to participate in the study; 5. Subject is willing and able to understand the purpose of the study, his/her role, and is available to return to the clinic/hospital for all required follow-up visits  Subjects will be excluded if, in the opinion of the Investigator, the subject does not qualify based on approved labeling requirements or Subject criteria